

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients

THOMPSON COBURN TRADE ALERT - IMPORTS

HEADLINE	Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
DATE	April 16, 2025
AGENCY	Department of Commerce; Trump Administration
EFFECTIVE DATES	Deadline to Submit Comments in Docket No. 250414-0065 - May 7, 2025 (21 Days after Publication Date)
BACKGROUND	<p>On April 1, 2025, the Trump Administration directed the Secretary of Commerce to conduct a 232 investigation into pharmaceuticals, pharmaceutical ingredients, and their derivative products to determine whether such imports impair the national security of the United States.</p> <p>The Department of Commerce's Bureau of Industry and Security is seeking written comments, data, and information related to the national security impacts of pharmaceuticals, pharmaceutical ingredients, and their derivative products.</p> <p>The Department is specifically interested in receiving comments and information regarding the following areas:</p> <ul style="list-style-type: none">• Current and future demand for pharmaceuticals and pharmaceutical ingredients• Ability of domestic production of pharmaceuticals and pharmaceutical ingredients to meet demand• Role of foreign supply chains, particularly from major exporters, in meeting U.S. demands
DETAILS	<ul style="list-style-type: none">• Concentration of U.S. pharmaceutical and pharmaceutical ingredients imports from a small number of suppliers and the associated risks• Impact of foreign government subsidies, overcapacity, and predatory trade practices on domestic industry competitiveness• Impact of low pharmaceutical and pharmaceutical ingredients prices due to unfair trade practices and state-sponsored overproduction• Risks from potential export restrictions by foreign nations• Feasibility of expanding domestic pharmaceutical production to reduce dependence on imports• Impact of current trade policies on domestic pharmaceutical production and whether additional measures, including tariffs or quotas, are necessary to protect national security

Please refer to the Notice linked below for filing instructions. Comments can be



submitted electronically at www.regulations.gov, ID: BIS-2025-0022, and all comments should refer to XRIN 0694-XC120

BASIS

Section 232 of the Trade Expansion Act of 1962; part 705 of the National Security Industrial Base Regulations (15 CFR parts 700 through 709)

CITE

[Federal Register: Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients](#)

authorsTest